IBB iShares Biotechnology ETF
Neutral Confidence 0.00 Regime Mid-vol · at high
No active arcs provided direction (all closed/contested or no arc coverage).
30-day verdict history
| Date | Direction | Confidence | Thesis |
|---|---|---|---|
| 2026-08-15 | Neutral | 0.00 | No active arcs provided direction (all closed/contested or no arc coverage). |
| 2026-08-14 | Neutral | 0.05 | Maintain a neutral stance (no one-sided judgment). Driven by arc 298 (us_healthcare_political_cycle): About 13 days after the event, non-price quantitative evidence has not conveyed arbitration/regulatory news into a substantive impact on IBB — with net inflows over the past 30 days (fund_flow_30d_pct_aum=2.64%), net inflows in the last 5 days, a decrease in short interest, and low and non-amplifying implied volatility (iv_rank 16%), these signals refute the conclusion that the market has experienced large-scale exodus or systemic damage. The arc is in a decaying state with low self-confidence, so continue to maintain neutral; no non-price chain has been found that can quantify regulatory news into earnings/provision impacts or passive weight impacts. |
| 2026-08-13 | Neutral | 0.05 | Maintain neutral stance; the driver is arc 298 (us_healthcare_political_cycle), with non-price evidence insufficient to translate regulatory/arbitration news into a one-sided impact on IBB. This arc is decaying (days_since_event=12, weaken_streak=4) and shows no outflows of capital (net creation +$61M since 2026-07-27, inflows up 2.27% AUM in the past 30 days), with short interest slightly down to about 11.9M (days-to-cover=6.42). Option IV is at historical lows and has decreased over the last five days—these non-price signals contradict a direct equivalence of regulatory news to systematic downside for IBB. Given the lack of new quantifiable transmission channels and evidence tilting neutral, maintain low-confidence neutral judgment. |
| 2026-08-12 | Neutral | 0.05 | Maintain Neutral Stance: The driving force is arc 298 (us_healthcare_political_cycle), which does not provide a non-price channel for regulatory/arbitration news to be transmitted to IBB funding flows or earnings expectations. Instead, non-price evidence shows that funds have not been withdrawn (net creation of +$61M since 2026-07-27, inflows of +2.27% AUM in the past 30 days), short interest is approximately 11.9M, and days-to-cover is 6.42. Option IV is at historical lows and has been declining over the last five days, which constitutes a counter-argument to one-sided bearish views. The arc remains decaying (weaken_streak=4, days_since_event≈11), thus maintaining a low-confidence neutral judgment. |
| 2026-08-11 | Neutral | 0.05 | Maintain a neutral stance, with the driver still being arc 298 (us_healthcare_political_cycle). The arc indicates that despite regulatory/CMS-related reports, there is no direct non-price chain linking arbitration payouts/regulatory progress to IBB cash flows or earnings expectations; instead, non-price data (net creation of +$61M since 2026-07-27, a 2.27% AUM inflow in the past 30 days, short interest approximately 11.9M with days-to-cover=6.42, and option IV at historical lows) constitutes counter-evidence to one-sided bearish views. The arc is currently decaying (weaken_streak=4, days_since_event=10.1), thus lacking new actionable evidence to alter the previous neutral judgment. |
| 2026-08-10 | Neutral | 0.04 | Maintain a neutral stance, with drivers still centered on arc 298 (us_healthcare_political_cycle). The arc acknowledges the presence of regulatory downside news (WSJ and CMS/Medicare documents) but does not provide evidence to connect 'arbitration awards/regulatory progress -> direct non-price transmission to IBB cash flows or earnings expectations.' Instead, non-price data serves as a counter-argument against one-sided bearish views: net creation since 2026-07-27 of +$61M (near 30-day +2.27% AUM), short interest at 11.9M with days-to-cover=6.42, ATM IV at historical lows, and the arc is decaying (weaken_streak=4, days_since_event=8.9); price_in is not marked, so confidence remains low. |
| 2026-08-09 | Neutral | 0.03 | Maintain neutral, low confidence. Drivers remain for arc 298 (us_healthcare_political_cycle): this arc signals regulatory downside risks but lacks proof connecting 'arbitration awards -> direct non-price evidence of IBB funding/profitability' to the ETF level; instead, net creations in the past 30 days are +$144M (+1.54% AUM), short interest slightly decreased to 11.9M shares, days-to-cover=6.42, and option IV is at only the 31st percentile with skew not indicating a clear demand for downside protection; these non-price signals do not support a one-sided bearish view. The arc state is decaying and weaken_streak=4, and window returns have partially reflected regulatory concerns, thus maintaining neutrality and low confidence. |
| 2026-08-08 | Neutral | 0.05 | Maintain neutral, low confidence. Drivers remain as arc 298 (us_healthcare_political_cycle): while the arc suggests a possibility of regulatory easing, there is no proof connecting the arbitration payouts to direct non-price evidence for IBB funds/profits at the ETF level. Instead, non-price data (net creations over the past 30 days of +$144M, slightly reduced short positions to 11.9M, low option IV and no significant skew indicating minimal demand for downside protection) along with in-window excess returns of -2.72% suggest that concerns may have been partially priced in, but there is insufficient evidence currently supporting a one-sided conclusion, hence maintaining a neutral stance with low confidence. |
| 2026-08-07 | Neutral | 0.06 | Maintain neutral, low confidence. Driven by arc 298 (us_healthcare_political_cycle): The Wall Street Journal reports on arbitration payouts and recent CMS/Medicare documents do indeed suggest regulatory downside, but there is a lack of non-price evidence linking these events to the ETF level. Instead, net creations of IBB of +$144M in the past 30 days (+1.54% AUM) and a slight decrease in short interest along with low option IV indicate that funds and risk premiums have not provided non-price signals supporting a one-sided bearish stance; prices are already partially factoring in (window excess return -2.72%), thus it is not advisable to continue maintaining a bearish conclusion. |
| 2026-08-06 | Bearish lean | 0.12 | 维持对 IBB 在 1–3 个月内偏空，但置信较低。驱动仍是 arc 298（US Healthcare Political Cycle）：WSJ 关于联邦仲裁的大额赔付线索与近 30 日 CMS/Medicare 文件构成监管/支付端下行风险，但缺乏将这些事件直接连到 ETF 层面的确证。相反，非价格证据——近 30 日净创设 +1.54% AUM、空头持仓小幅下降与期权 IV 处于低位——抵消了单边看空论据；价格也已部分反映监管担忧，因此保持温和偏空并压低置信度。 |
| 2026-08-05 | Bearish lean | 0.20 | Maintain a bearish stance on IBB for 1-3 months. The driver remains arc 298: reports from the WSJ about large jury awards in federal arbitrations and recent CMS/Medicare documents pose non-price downside risks to industry regulation/payment, but there is currently no confirmation linking these events to the ETF level (no direct evidence of net outflows or deteriorating earnings forecasts). Meanwhile, a net creation over the past 30 days (+1.56% AUM), slightly reduced short positions, and option IV at median levels offset some bearish arguments, thus lowering confidence to a medium-low level. |
| 2026-08-04 | Bearish lean | 0.28 | Maintain a bearish stance on IBB for the next 1-3 months. The driver remains the non-price evidence from arc 298 (US Healthcare Political Cycle): reports from the WSJ about large jury awards in federal arbitration cases, along with CMS/Medicare documents over the past 30 days, pose a downside risk to industry regulation and payments but lack new quantitative connectivity evidence to definitively amplify this impact. It should be noted that price factors have already been partially factored in (price_in flag=True, cumulative excess -4.18%), and there are offsetting signals such as net inflows of +1.56% AUM and a slight decrease in short positions during the same period, which lower our confidence to a medium-low level. |
| 2026-08-03 | Bearish lean | 0.36 | Maintain a bearish bias on IBB for 1-3 months. The driver remains the non-price evidence from arc 298 (US Healthcare Political Cycle): reports from the WSJ about large jury awards for federal arbitration and three CMS/Medicare documents in the past 30 days pose regulatory and payment downside risks to the healthcare/biopharmaceutical sector. This arc has been weakened (strengthen_streak=0, weaken_streak=2), with a simultaneous offset signal – net inflows of +1.56% AUM over 30 days, no panic pricing in options, and slightly reduced short positions – thus I have lowered my confidence to medium-low; the price has already partially reflected this (-2.49% price_in_excess). |
| 2026-08-02 | Bearish lean | 0.48 | Maintain a bearish bias on IBB for 1-3 months. Driven by arc 298 (US Healthcare Political Cycle): large WSJ payments regarding federal arbitration (event_opp #2477) and three recent CMS/Medicare documents, which constitute independent, non-price evidence pointing to regulatory/payment risks for the industry. The arc's strength has weakened compared to the previous assessment (strengthen_streak=0, weaken_streak=1), and prices have partially reflected this (-2.49%, flagged=False). With mixed quantitative signals such as fund flows and short coverings, confidence is moderately reduced. |
| 2026-08-01 | Bearish lean | 0.55 | Maintain a bearish bias on IBB for 1-3 months. Driven by arc 298 (US Healthcare Political Cycle): reports from the WSJ about large payments from federal arbitration mechanisms (event_opp #2477) and three CMS/Medicare documents in the past 30 days, constituting independent non-price evidence that reinforces the downward trajectory for industry profitability due to regulatory/payment system pressures. Quantitative signals indicate the event is fresh (days_since_event=0.1, strengthen_streak=1) and price_in marked as False (-2.49% accumulation not fully priced in), thus increasing confidence; however, high days-to-cover (6.42), recent inflows of capital, and neutral IV rankings provide some cushion against the decline, resulting in a moderately high confidence level. |
| 2026-07-31 | Bearish lean | 0.35 | Maintain a bearish stance on IBB for the next 1-3 months, driven by non-price evidence from arc 298 (US Healthcare Political Cycle). The arc indicates three CMS/Medicare documents related to drug pricing in the past 30 days. Option ATM IV and IV rank have increased, along with a slight decline in federal net liquidity, pointing to downside risks from regulatory/hedging needs; however, high days-to-cover and inflows provide some cushion against declines, so it is not a one-sided bet. Given that this arc is nascent, days_since_event=10 (>7 days), and strengthen_streak=0, the evidence is not fresh or robust enough to warrant higher confidence (confidence level set at 0.35); price_in is marked as False, with movements not explicitly factored into pricing. |
| 2026-07-30 | Neutral | 0.25 | Maintain neutral. Driven by arc 298 (US Healthcare Political Cycle): Non-price evidence shows three CMS/pharmacy-related documents in the past 30 days, accompanied by an increase in ATM IV/IV rank (high IV rank and upward IV), indicating regulatory uncertainty being factored into risk premiums; however, rising federal net liquidity (+127B/4w) and higher days-to-cover (6.42) provide substantial cushion for the sector. This arc is nascent/contested (days_since_event=9, strengthen_streak=0, weaken_streak=2), with conflicting and not sufficiently fresh or one-sided evidence, and price_in marked as False; hence, maintain neutral with low confidence. |
| 2026-07-29 | Neutral | 0.25 | Maintain neutral stance. Driven by arc 298 (US Healthcare Political Cycle): Non-price evidence indicates that there are still three CMS/pharmacy-related documents in the past 30 days, and the ATM IV and IV rank (86%) have risen, indicating that regulatory/policy uncertainty is being factored into risk premiums; however, Fed net liquidity remains high ($5,916B), VIX term structure is in contango, and higher days-to-cover (6.42) provide substantial cushion for the sector. Current evidence suggests a conflict/initial state (days_since_event≈8.1, strengthen_streak=0, weaken_streak=2), with price_in marked as False, hence no change in direction, maintaining low-confidence neutral watch. |
| 2026-07-28 | Neutral | 0.25 | 维持中性。驱动判断来自 arc 298（US Healthcare Political Cycle）的非价格证据：近30日CMS/药价相关文件=3份，提示制度性下行风险，但同期联储净流动性在过去4周增加+$107B、VIX期结构处于contango且HY OAS未显著走阔，为板块提供实质性缓冲；另外高位空头与较长的 days-to-cover（约6.42）增加逼空可能性。当前 strengthen_streak=0 且 days_since_event≈7，证据互相抵消且未形成新鲜确认性催化，故维持低置信度中性立场（price_in 未标注为已计入）。 |
| 2026-07-27 | Neutral | 0.25 | Maintain neutral. Mainly based on non-price evidence from arc 298 (US Healthcare Political Cycle): there are 3 CMS/pharmacy-related documents in the past 30 days, indicating downward structural pressure, but at the same time, the Federal Reserve's net liquidity has increased by +$107B over the past 4 weeks and the VIX term structure is in contango (ratio=0.858), providing substantial cushion for the sector; crowded short positions (short shares ≈ 11.9M, days-to-cover=6.42) also limit short-term one-sided declines. Given that this arc remains nascent and evidence offsets each other with strengthen_streak=0, maintain a low-confidence neutral stance as there is no sufficient independent non-price catalyst to drive a clear direction. |
| 2026-07-26 | Neutral | 0.30 | Maintain Neutral: The two dominant arcs offset each other on non-price evidence and are not sufficient to change the previous conclusion. Arc 346 (Medicare/IRA) provides quantitative evidence of systemic downside risk—over the past 30 days, there have been 3 CMS/drug_pricing documents; arc 298 has direct signals for reimbursement/demand (Obamacare enrollment dropped from 22.1M to 19.2M), but at the same time, systemic liquidity and risk indicators (Fed net liquidity $5,917B/4 weeks +$107B, VIX term ratio=0.906) provide a significant buffer for risk assets. Given that arc 346 is somewhat outdated (days_since_event=15, strengthen_streak=0), and both arcs are nascent/contested with price_in marked as false, maintain a low-confidence neutral stance. |
| 2026-07-25 | Neutral | 0.30 | Maintain Neutral: The two dominant arcs (arc 346 for Medicare/IRA drug pricing regime risk and arc 298 for US healthcare/political cycle disclosure) remain in their nascent or contested states, with non-price evidence offsetting each other, and no quantifiable and verifiable regulatory pricing outcomes to unilaterally determine the direction. Specifically, supportive evidence for arc 346 includes an increase from 2 to 3 CMS/drug_pricing documents in the past 30 days (indicating potential systemic downside risk), but this arc is somewhat outdated (days_since_event=14.1 and strengthen_streak=0). Meanwhile, arc 298 provides direct quantifiable evidence for a downward trend (declining enrollment disclosures) and is more recent (days_since_event=4.1). Together, these do not outweigh the buffer provided by liquidity/risk towards risk assets (Regime: Fed net liquidity rising, VIX term ratio in contango). Therefore, stance remains unchanged despite recent price movements, maintaining a neutral position while keeping an eye on arc 346 for any substantive pricing/negotiation outcomes that could drive changes. |
| 2026-07-24 | Neutral | 0.30 | Maintain neutral. The driving factors come from arc 346 (Medicare/IRA CMS-related documents increased from 2 to 3 in the past 30 days, signaling potential systemic drug pricing/reimbursement risks) and arc 298 (disclosures on US healthcare/poliitical cycle and declining insured population), but both arcs are nascent with a strengthen_streak of 0, non-price evidence offsetting each other: regulatory documents slightly increasing point to downside risks, while macro liquidity (Fed net liquidity ~$5,986B), the contango in the VIX curve, and HY OAS not widening significantly provide mild support for risk assets; no clear and quantifiable non-price catalysts are currently evident to unilaterally validate a direction, hence maintaining neutral. A clear CMS pricing rule or other verifiable regulatory catalyst (to be provided by arc 346) would require re-evaluation of the direction. |
| 2026-07-23 | Neutral | 0.30 | Maintain neutral. The main drivers are arc 346 (Medicare IRA drug price negotiation, CMS related documents in the past 30 days = 2) and arc 298 (US healthcare/policy cycle, systemic pressure on reimbursement/coverage), both of which provide nascent non-price evidence pointing to regulatory/reimbursement risks but have a strengthen_streak=0 and lack clear quantifiable catalysts (price_in marked as False). Offsetting non-price evidence includes a recent four-week increase in net liquidity (+$137B Fed net liquidity) and the VIX curve in contango, providing mild support for risk assets. Therefore, maintain a neutral stance until new verifiable non-price catalysts emerge. |
| 2026-07-22 | Neutral | 0.40 | Maintain a neutral stance. Arc 346 (Medicare IRA) presents non-price evidence of regulatory/pricing risks (CMS has seen an increase in related documents over the past 30 days), but at the same time, macro liquidity is rising (+$137B from the Fed) and VIX term structure is in contango, providing mild support to risk assets; these two factors offset each other. Arc 298 indicates a decline in ACA enrollees with premium increases on the insurance side, creating systemic pressure on medical payments/reimbursements, but the transmission path to biopharmaceuticals (IBB) is indirect and mixed. Both arcs are nascent and have a strengthen_streak of 0, with price_in marked as False, lacking one-sided, quantifiable non-price catalysts; therefore, maintain a neutral stance over the 1-3 month horizon. |
| 2026-07-21 | Neutral | 0.39 | Maintain a neutral stance. Both arcs are nascent and directionally contested: the non-price evidence provided by arc 346 (Medicare IRA) is regulatory/pricing pressure (increased CMS filings, borrowing fees/short squeeze warnings), but macro liquidity recovery and the VIX term structure supporting risk assets offset this evidence; the latest disclosure for arc 298 (US Healthcare Political Cycle) shows a decrease in enrollment and premium hikes, adding uncertainty to the insurance end, but its impact on biotech companies is indirect and mixed. Given the lack of one-sided, verifiable non-price catalysts (neither arc has a strengthen_streak and price_in is marked as False), there is no basis to change position direction; hence, maintain neutrality with low confidence. |
| 2026-07-20 | Neutral | 0.38 | Maintain a neutral stance. The primary driver is arc 346 (Medicare IRA Drug Pricing Cycle): mixed non-price evidence – on one hand, Fed net liquidity has risen ($5,987B, 4w +$131B) supported by a contango VIX term structure which underpins risk asset exposure; on the other hand, an increase in CMS/pharmacy negotiation documents and rising IBB bond yields (≈1.94%) pose regulatory and shorting costs to the sector. The arc remains nascent with days_since_event=9 and strengthen_streak=0, lacking clear non-price catalysts or sustained confirmations; and there are signs of partial price realization (price_in_excess ≈+0.98%), thus it is not advisable to increase directional positions or confidence levels. |
| 2026-07-19 | Neutral | 0.30 | Maintain neutral. The main driving arc is Arc 346: a mix of non-price evidence – on one hand, Fed net liquidity has risen and the VIX term structure is in contango, theoretically supporting risk assets; on the other hand, CMS negotiations with drug prices and increased borrowing costs for biotech bonds (around 1.94%) impose regulatory/cost constraints on the biotech sector. This arc is nascent and days_since_event=8, strengthen_streak=0, lacking recent confirming non-price catalysts, thus it is not advisable to increase directional positions or confidence levels. |
| 2026-07-18 | Neutral | 0.28 | Continue to maintain a neutral stance. The price-neutral driver from arc 298 (US healthcare political cycle): weak June non-farm data -> lower probability of tightening -> theoretically supportive for growth/biotech sectors, but this arc is decaying and its quantitative readings contradict the bullish arguments (excess_sigma=-0.25, weaken_streak=3, vol_flow=bearish_surge), thus it cannot be used as a basis for entering positions. The new arc 346 (drug_pricing_ira_medicare_cycle) is nascent and in a contested state: mixed non-price evidence - liquidity support for risk assets but regulatory documents/pricing pressures exist, with partial price reflection in the short window (price_in_excess ≈ +0.98%), making the direction still uncertain. |
| 2026-07-17 | Neutral | 0.20 | Maintain neutral stance: The non-price chain proposed by arc 298 (US healthcare political cycle), such as the significantly weaker June non-farm data -> reducing tightening probability -> benefiting high-valued growth stocks, still exists but lacks new independent non-price confirmations. Moreover, its quantitative evidence contradicts the bullish arguments (excess_sigma=-0.25, weaken_streak=3, vol_flow=bearish_surge), making it unsuitable as a basis for opening positions. Most of the impact from arc 62 (Hantavirus) has been priced in by the market (price_in_excess=+10.83%, flagged=True) and has diminished over time, lacking additional non-price support. Therefore: On one hand, there are quantified signals negating macro-bullish arguments, while on the other hand, event shocks have already been reflected in prices. Hence, maintain a neutral stance with low confidence. |